Parathyroid hormone (PTH), produced by the parathyroid glands, plays a critical and well-understood role in regulating calcium and phosphate balance in the body, which is fundamental for skeletal health. Scientifically, PTH increases blood calcium levels by stimulating osteoclasts to break down bone and release calcium, increasing intestinal absorption of calcium via activation of vitamin D, and reducing calcium loss in urine. These effects support bone remodeling and calcium homeostasis, both of which are essential for maintaining healthy bones.

Synthetic or recombinant parathyroid hormone (e.g., teriparatide) is an FDA-approved medication used to treat osteoporosis in patients at high risk for fracture. Clinical studies have demonstrated that intermittent administration of teriparatide stimulates new bone formation and increases bone mineral density, thereby reducing fracture risk in postmenopausal women and men with osteoporosis. This represents strong scientific validation for the use of parathyroid-based therapy in supporting the skeletal system.

However, use of actual animal parathyroid gland extracts as a supplement is not common or recommended due to safety, regulatory, and efficacy concerns. The primary, evidence-based support for the skeletal system comes from regulated pharmaceutical preparations of parathyroid hormone, not from dietary supplements or traditional use of parathyroid tissue.